results . Clin Cancer Res 2005 ; 11 [ suppl 13 ]: 4984 – 4987 . 16. Kato H Ichinose Y Ohta M . A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung . N Engl J Med 2004 ; 350 : 1713 – 1721
Search Results
Rebecca P. Petersen and David H. Harpole Jr.
David C. Dale, Gordon C. McCarter, Jeffrey Crawford, and Gary H. Lyman
results of 20 years of follow-up . N Engl J Med 1995 ; 332 : 901 – 906 . 2 Wood WC Budman DR Korzun AH . Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma . N Engl J Med 1994 ; 330 : 1253
Scott M. Schuetze
sarcoma: eight-year experience with adjuvant chemotherapy . J Cancer Res Clin Oncol 1983 ; 106 ( suppl ): 55 – 67 . 16. Sutow WW Sullivan MP Fernbach DJ . Adjuvant chemotherapy in primary treatment of osteogenic sarcoma. A Southwest Oncology
Al B. Benson III, Tanios Bekaii-Saab, Emily Chan, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Paul F. Engstrom, Peter C. Enzinger, Marwan G. Fakih, Moon J. Fenton, Charles S. Fuchs, Jean L. Grem, Steven Hunt, Ahmed Kamel, Lucille A. Leong, Edward Lin, Kilian Salerno May, Mary F. Mulcahy, Kate Murphy, Eric Rohren, David P. Ryan, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, William Small Jr, Constantinos T. Sofocleous, Alan P. Venook, Christopher G. Willett, Kristina M. Gregory, and Deborah A. Freedman-Cass
rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®. Adjuvant Therapy for Stage II Disease The panel discussed the impact of adjuvant chemotherapy on
Lingling Du and Andrea Wang-Gillam
Neoadjuvant Approach Phase III trials have demonstrated a clear survival benefit with adjuvant chemotherapy. 5 , 7 Multiple studies examined neoadjuvant therapy as an alternative to the traditional adjuvant approach. Neoadjuvant therapy offers patients the
Natasha Satkunam, Xuejiao Wei, James J. Biagi, Sulaiman Nanji, and Christopher M. Booth
Background Adjuvant chemotherapy (ACT) with 5-fluorouracil (FU) has been the standard of care for stage III or high-risk stage II colon cancer since the 1990s. 1 This treatment is based on a series of randomized clinical trials (RCTs) showing
Peter E. Clark, Philippe E. Spiess, Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, Jason A. Efstathiou, Thomas W. Flaig, Terence Friedlander, Richard E. Greenberg, Khurshid A. Guru, Noah Hahn, Harry W. Herr, Christopher Hoimes, Brant A. Inman, A. Karim Kader, Adam S. Kibel, Timothy M. Kuzel, Subodh M. Lele, Joshua J. Meeks, Jeff Michalski, Jeffrey S. Montgomery, Lance C. Pagliaro, Sumanta K. Pal, Anthony Patterson, Daniel Petrylak, Elizabeth R. Plimack, Kamal S. Pohar, Michael P. Porter, Wade J. Sexton, Arlene O. Siefker-Radtke, Guru Sonpavde, Jonathan Tward, Geoffrey Wile, Mary A. Dwyer, and Courtney Smith
of adjuvant systemic chemotherapy in invasive bladder cancer. Studies have shown that adjuvant chemotherapy may delay recurrences and improve OS, 41 – 43 but no randomized comparisons of adequate sample size have definitively shown a survival benefit
Robert E. Smith Jr.
://www.nccn.org . Accessed May 23, 2006 . 4. Kim ES Vokes EE Kies MS . Cetuximab in cancers of the lung and head & neck . Semin Oncol 2004 ; 31 ( suppl 1 ): 61 – 67 . 5. Hryniuk W Levine MN . Analysis of dose intensity for adjuvant chemotherapy
Wells A. Messersmith
NCCN Guidelines, despite not being FDA-approved for this indication, because the data are “so compelling,” he added. Dr. Messersmith focused mainly on 2 combination therapies for adjuvant chemotherapy for resected (primary) colon cancer: FOLFOX
Pranab Kumar Sahoo, Sinjini Sarkar, Sutapa Mahata, Ranita Pal, Tanuma Mistry, Sushmita Ghosh, Trisha Choudhury, Sriparna Datta, Anup Kumar Bhowmick, Kalyan Kusum Mukherjee, and Vilas D Nasare
maximum number of patients diagnosed with SCC (36%) received adjuvant chemotherapy (56.7%). 25.6% patients underwent TPF chemotherapy while 74.4% of patients went for PC chemotherapeutic regimen. Patients mainly experienced grade III and IV haematological
